University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
Bradley A. Stohr, MD, PhD

Bradley A. Stohr, MD, PhD

Assistant Professor, Department of Pathology, UCSF
Stuart Lindsay Endowed Professorship in Experimental Pathology III, UCSF

Cancer Center Program Memberships

Non-aligned

Education

Swarthmore College, Swarthmore, PA, BA, 1995, Biology
Duke University, Durham, NC, PhD, 2002, Microbiology
Duke University, Durham, NC, MD, 2003, Medicine
University of California, San Francisco, CA, Resident/Fellow, 2003-2006, Anatomic Pathology
University of California, San Francisco, CA, Postdoctoral Fellow, 2005-2008, Biochemistry


Professional Experience

  • 1993-1994
    Research Assistant, Jackson Laboratory. Advisor: Sandya Narayanswami, Ph.D.
  • 1995-1996
    Research Assistant, Department of Microbiology, University of California, Davis. Advisor: Satya Dandekar, Ph.D.
  • 1998-2002
    Graduate Student, Department of Microbiology, Duke University Advisor: Kenneth Kreuzer, Ph.D.
  • 2003-2006
    Resident/Fellow, Anatomic Pathology, University of California, San Francisco
  • 2005-2008
    Postdoctoral Fellow, Department of Biochemistry, University of California, San Francisco Advisor: Elizabeth Blackburn, Ph.D.
  • 2008-2010
    Clinical Instructor, Department of Pathology, University of California, San Francisco

Honors & Awards

  • 1995
    Phi Beta Kappa honor society
  • 1995
    Sigma Xi honor society
  • 1996-2003
    Medical Scientist Training Program Fellowship
  • 2005
    Ruth L. Kirschstein Postdoctoral Fellowship (declined)
  • 2005-2008
    American Cancer Society Postdoctoral Fellowship
  • 2010-present
    Mentored Clinical Scientist Development Award (K08)

Selected Publications

  1. Lei L, Stohr BA, Berry S, Lockwood CM, Davis JL, Rudzinski ER, Kunder CA. Recurrent EGFR alterations in NTRK3 fusion negative congenital mesoblastic nephroma. Pract Lab Med. 2020 Aug; 21:e00164.
    View on PubMed
  2. Chan E, Stohr BA, Croom NA, Cho SJ, Garg K, Troxell ML, Higgins JP, Bean GR. Molecular characterisation of metanephric adenomas beyond BRAF: genetic evidence for potential malignant evolution. Histopathology. 2020 Jun; 76(7):1084-1090.
    View on PubMed
  3. Shah RB, Stohr BA, Tu ZJ, Gao Y, Przybycin CG, Nguyen J, Cox RM, Rashid-Kolvear F, Weindel MD, Farkas DH, Trpkov K, McKenney JK. "Renal Cell Carcinoma With Leiomyomatous Stroma" Harbor Somatic Mutations of TSC1, TSC2, MTOR, and/or ELOC (TCEB1): Clinicopathologic and Molecular Characterization of 18 Sporadic Tumors Supports a Distinct Entity. Am J Surg Pathol. 2020 May; 44(5):571-581.
    View on PubMed
  4. Chan E, Garg K, Stohr BA. Integrated immunohistochemical and molecular analysis improves diagnosis of high-grade carcinoma in the urinary bladder of patients with prior radiation therapy for prostate cancer. Mod Pathol. 2020 Apr 20.
    View on PubMed
  5. Greenland NY, Cowan JE, Zhang L, Carroll PR, Chan E, Stohr BA, Simko JP. Expansile cribriform Gleason pattern 4 has histopathologic and molecular features of aggressiveness and greater risk of biochemical failure compared to glomerulation Gleason pattern 4. Prostate. 2020 May; 80(8):653-659.
    View on PubMed
  6. Chen F, Jimenez RJ, Sharma K, Luu HY, Hsu BY, Ravindranathan A, Stohr BA, Willenbring H. Broad Distribution of Hepatocyte Proliferation in Liver Homeostasis and Regeneration. Cell Stem Cell. 2020 Jan 02; 26(1):27-33.e4.
    View on PubMed
  7. Ravindranathan A, Diolaiti ME, Cimini BA, Stohr BA. In Situ Visualization of Telomere Length, Telomere Elongation, and TERT Expression in Single Cells. Curr Protoc Cell Biol. 2019 12; 85(1):e97.
    View on PubMed
  8. Fergus KB, Lee AW, Baradaran N, Cohen AJ, Stohr BA, Erickson BA, Mmonu NA, Breyer BN. Pathophysiology, Clinical Manifestations, and Treatment of Lichen Sclerosus: A Systematic Review. Urology. 2020 Jan; 135:11-19.
    View on PubMed
  9. Sirohi D, Devine P, Grenert JP, van Ziffle J, Simko JP, Stohr BA. TP53 structural variants in metastatic prostatic carcinoma. PLoS One. 2019; 14(6):e0218618.
    View on PubMed
  10. Greenland NY, Zhang L, Cowan JE, Carroll PR, Stohr BA, Simko JP. Correlation of a Commercial Genomic Risk Classifier with Histological Patterns in Prostate Cancer. J Urol. 2019 07; 202(1):90-95.
    View on PubMed
  11. Davis JL, Lockwood CM, Stohr B, Boecking C, Al-Ibraheemi A, DuBois SG, Vargas SO, Black JO, Cox MC, Luquette M, Turpin B, Szabo S, Laetsch TW, Albert CM, Parham DM, Hawkins DS, Rudzinski ER. Expanding the Spectrum of Pediatric NTRK-rearranged Mesenchymal Tumors. Am J Surg Pathol. 2019 04; 43(4):435-445.
    View on PubMed
  12. Kyle Brian Zuniga, Samuel L. Washington, Jeffry Simko, Nancy Greenland, Bradley A. Stohr, Janet E. Cowan, Imelda Tenggara, Martina Maggi, June M. Chan, Matthew R. Cooperberg, Peter Carroll. Cribriform pattern, Genomic Prostate Score, and adverse pathology at radical prostatectomy in a cohort of prostate cancer patients initially on active surveillance. Journal of Clinical Oncology. 2019 Mar 1; 37(7_suppl):88-88.
    View on PubMed
  13. Ravindranathan A, Cimini B, Diolaiti ME, Stohr BA. Preliminary development of an assay for detection of TERT expression, telomere length, and telomere elongation in single cells. PLoS One. 2018; 13(12):e0206525.
    View on PubMed
  14. Leapman MS, Nguyen HG, Cowan JE, Xue L, Stohr B, Simko J, Cooperberg MR, Carroll PR. Comparing Prognostic Utility of a Single-marker Immunohistochemistry Approach with Commercial Gene Expression Profiling Following Radical Prostatectomy. Eur Urol. 2018 11; 74(5):668-675.
    View on PubMed
  15. Rudzinski ER, Lockwood CM, Stohr BA, Vargas SO, Sheridan R, Black JO, Rajaram V, Laetsch TW, Davis JL. Pan-Trk Immunohistochemistry Identifies NTRK Rearrangements in Pediatric Mesenchymal Tumors. Am J Surg Pathol. 2018 07; 42(7):927-935.
    View on PubMed
  16. Sirohi D, Vaske C, Sanborn Z, Smith SC, Don MD, Lindsey KG, Federman S, Vankalakunti M, Koo J, Bose S, Peralta-Venturina M, Ziffle JV, Grenert JP, Miller S, Chiu C, Amin MB, Simko JP, Stohr BA, Luthringer DJ. Polyoma virus-associated carcinomas of the urologic tract: a clinicopathologic and molecular study. Mod Pathol. 2018 09; 31(9):1429-1441.
    View on PubMed
  17. Michael Leapman, Hao Nguyen, Janet Cowan, Lingru Xue, Bradley Stohr, Jeffry Simko, Matthew Cooperberg, Peter Carroll. PD56-12 COMPARISON OF A LOW-COST IMMUNOHISTOCHEMISTRY MARKER PANEL WITH A CELL-CYCLE PROGRESSION ASSAY FOR THE PREDICTION OF OUTCOME AFTER RADICAL PROSTATECTOMY. The Journal of Urology. 2018 Apr 1; 199(4):e1066.
    View on PubMed
  18. Michael Leapman, Hao Gia Nguyen, Janet E. Cowan, Lingru Xue, Bradley Stohr, Jeffry Simko, Matthew R. Cooperberg, Peter Carroll. Comparison of a low-cost immunohistochemistry marker panel with a cell-cycle progression assay for the prediction of outcome after radical prostatectomy. Journal of Clinical Oncology. 2018 Feb 20; 36(6_suppl):118-118.
    View on PubMed
  19. Williamson SR, Grignon DJ, Calió A, Stohr BA, Eble JN, Cheng L. Reply to Chou et al 'Do significant TFE3 gene rearrangements occur in succinate dehydrogenase deficient renal cell carcinoma? Borderline FISH results should be interpreted with caution' Mod Pathol 2017; in press. Mod Pathol. 2017 10; 30(10):1509-1511.
    View on PubMed
  20. Wolfgang Michael Korn, Iwei Yey, Jessica Van Ziffle, James P Grenert, Nancy Joseph, David A. Solomon, Megan Laurance, Eric Talevich, Courtney Onodera, Gregor Krings, Bradley A. Stohr, Amie Blanco, Boris C. Bastian. Targeted next-generation DNA sequencing of paired tumor and normal DNA to reveal frequent actionable germline alterations. Journal of Clinical Oncology. 2017 May 20; 35(15_suppl):11575-11575.
    View on PubMed

Go to UCSF Profiles, powered by CTSI